Advanced Wound Closure's New Players - Health Works Collective

Advanced Wound Closure’s New Players

The global market for products in “wound securement,” or the aggregate of products that are related to the closure and healing of wounds, is dominated by traditional products — sutures and the more recent clips and staples. However, as simple and effective as these are, particularly since their use is engrained in the skillsets of practicing surgeons, advances in wound closure, hemostasis and even anti-adhesion are challenging the entrenched positions of suture, staple and clip suppliers.

Fibrin and other sealants have found acceptance in use by surgeons seeking tighter wound sealing, faster healing, less scarring and other benefits. Hemostatic agents have proven highly versatile (in a range of clinical settings from the OR to the battlefield) in rapidly stopping bleeds in a way that traditional wound closure cannot. The end result of surgery also demands that the surgery itself cause a minimum of complications, and products in anti-adhesion (many actually being sealant products that are actually effective in what one might consider the “opposite” role) have proved effective in this capacity.

But old habits die hard, so very high caseload of wound closure is still addressed via sutures, staples and clips. Consequently, the global market for wound closure and related products has companies like Ethicon (J&J) holding big pieces of the pies.

Legend:

A: Ethicon/J&J
B: Covidien
C: B. Braun
D: Others
E: 3M
F: CSL Behring
G: Pfizer
H: Equimedical BV
I: Baxter
J: Cryolife
K: AdMedSol
L: Genzyme Biosurgery

Source: “Worldwide Surgical Sealants, Glues, Wound Closure and Anti-Adhesion Markets, 2012-2017″, MedMarket Diligence Report #S190.

Author

PatrickDriscoll

I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.

View all posts by PatrickDriscoll

Where Is The Balance? Pushing Back Against Consumer Health Tech

Larry Alton - August 18, 2017

When Republican Congressman Jason Chaffetz glibly remarked that Americans struggling to afford insurance should choose between that and their smartphones,…